Monovalent pneumococcal conjugate vaccine - Pfizer
Alternative Names: mPnC; mPnC - PfizerLatest Information Update: 18 Jun 2024
At a glance
- Originator Pfizer
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pneumococcal infections
Most Recent Events
- 27 May 2024 Pfizer completes a phase-II clinical trials in Pneumococcal infections (Prevention, In infants) in Finland and Poland (unspecified route) (NCT06116591) (EudraCT2023-505154-18-00)
- 09 Nov 2023 Pfizer plans a phase II trial for Pneumococcal infections (In infants, Prevention) (NCT06116591)
- 09 Nov 2023 Preclinical trials in Pneumococcal infections (Prevention) in USA (unspecified route), before November 2023